Brief: MiNK Therapeutics Q2 EPS USD -0.62
Mink Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
Brief: MiNK Therapeutics Says No Major Serious Adverse Events Attributed To Agent-797 In First Patients
U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's
U.S. STOCKS ON THE MOVE-Dave, Quanta Services, Union Pacific Corp
MiNK Therapeutics jumps after first patient dosed in lung injury study
MiNK Therapeutics' Q1 net loss narrows slightly
Brief: MiNK Therapeutics Q1 EPS USD -0.57
Brief: MiNK Therapeutics And First Lviv Territorial Medical Union Initiate Randomized Phase 2 Trial Of Agent-797 In Acute Lung Injury And Critical Illness
Brief: Mink Therapeutics Says Co Discussing Potential Combination Trials & Strategic Minority Investments
Brief: Mink Therapeutics To Report Fourth Quarter And Full Year 2025 Financial Results And Highlight Platform Expansion Across Inkt Cell Therapy Programs
U.S. STOCKS ON THE MOVE-Nuwellis, Citigroup, Meta
U.S. STOCKS ON THE MOVE-GE Vernova, Atlas Energy, Citigroup
U.S. STOCKS ON THE MOVE-Rivian, Bunge, Vertex
U.S. STOCKS ON THE MOVE-Crypto stocks, MiNK Therapeutics, AtaiBeckley
AtaiBeckley rises as depression drug moves toward late‑stage trials
MiNK Therapeutics rises as it wins funding for child cancer cell therapy
Brief: MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy
Brief: Mink Therapeutics Inc - Files For Mixed Shelf Offering Up To $150 Million - SEC Filing